Studies why some myeloma patients respond to teclistamab and others do not
Examines immune and genetic features in multiple myeloma patients treated with teclistamab.
Plain-language title generated from the registry record
Registry title: Analysis of the Resistance and Sensitivity Mechanisms to Teclistamab by Focusing on Single Immune Cell Examination
Key facts
- Where
- Amiens, Caen, Dijon, Epagny Metz- Tessy, Lille, Lyon, Montpellier, Paris, Pessac, Pierre-Bénite, Poitiers, Rennes, Saint-Priest-en-Jarez, Toulouse, Tours, and Vandœuvre-lès-Nancy, FranceSee the 18 sites
Where in France
- CHU D'amiensAmiens, FranceTaking people
- CHU de CAENCaen, FranceTaking people
- Polyclinique du Parc DrevonDijon, FranceTaking people
- CH Annecy GenevoisEpagny Metz- Tessy, FranceTaking people
- CHU de LilleLille, FranceTaking people
- Centre Leon BerardLyon, FranceTaking people
- CHU de MontpellierMontpellier, FranceTaking people
- Hôpital NeckerParis, FranceTaking people
- Hopital Saint LouisParis, FranceTaking people
- Hôpital Saint-AntoineParis, FranceTaking people
- CHU de BordeauxPessac, FranceTaking people
- CHU de LyonPierre-Bénite, FranceTaking people
- CHU de PoitiersPoitiers, FranceTaking people
- CHU de RennesRennes, FranceTaking people
- CH Saint-EtienneSaint-Priest-en-Jarez, FranceTaking people
- CHU de ToulouseToulouse, FranceTaking people
- CHU de ToursTours, FranceTaking people
- CHRU NancyVandœuvre-lès-Nancy, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Toulouse
- Trial code
- NCT05945524
- Record updated
- 10 April 2025
- Original description
The aim of this study is to discover the immune and oncogenomic features that distinguish patients who respond to teclistamab from patients who are primarily resistant. Moreover, phenotypic and genotypic characteristics that occur with secondary resistance to teclistamab will be analyzed.Read full original descriptionShow less
Analysis of the Resistance and Sensitivity Mechanisms to Teclistamab by Focusing on Single Immune Cell Examination
The aim of this study is to discover the immune and oncogenomic features that distinguish patients who respond to teclistamab from patients who are primarily resistant. Moreover, phenotypic and genotypic characteristics that occur with secondary resistance to teclistamab will be analyzed.
Inclusion: With multiple myeloma; Who receive Teclistamab; Consent form signed.
Exclusion: Patient under legal protection.